Literature DB >> 25190750

Driving toward targeted therapy for LCH.

Robert A Baiocchi1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25190750      PMCID： PMC4155264          DOI： 10.1182/blood-2014-07-587378

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  High prevalence of somatic MAP2K1 mutations in BRAF V600E-negative Langerhans cell histiocytosis.

Authors:  Noah A Brown; Larissa V Furtado; Bryan L Betz; Mark J Kiel; Helmut C Weigelin; Megan S Lim; Kojo S J Elenitoba-Johnson
Journal:  Blood       Date:  2014-06-30       Impact factor: 22.113

2.  Transformation of mammalian cells by constitutively active MAP kinase kinase.

Authors:  S J Mansour; W T Matten; A S Hermann; J M Candia; S Rong; K Fukasawa; G F Vande Woude; N G Ahn
Journal:  Science       Date:  1994-08-12       Impact factor: 47.728

3.  Exome sequencing identifies recurrent somatic MAP2K1 and MAP2K2 mutations in melanoma.

Authors:  Sergey I Nikolaev; Donata Rimoldi; Christian Iseli; Armand Valsesia; Daniel Robyr; Corinne Gehrig; Keith Harshman; Michel Guipponi; Olesya Bukach; Vincent Zoete; Olivier Michielin; Katja Muehlethaler; Daniel Speiser; Jacques S Beckmann; Ioannis Xenarios; Thanos D Halazonetis; C Victor Jongeneel; Brian J Stevenson; Stylianos E Antonarakis
Journal:  Nat Genet       Date:  2011-12-25       Impact factor: 38.330

4.  Recurrent BRAF mutations in Langerhans cell histiocytosis.

Authors:  Gayane Badalian-Very; Jo-Anne Vergilio; Barbara A Degar; Laura E MacConaill; Barbara Brandner; Monica L Calicchio; Frank C Kuo; Azra H Ligon; Kristen E Stevenson; Sarah M Kehoe; Levi A Garraway; William C Hahn; Matthew Meyerson; Mark D Fleming; Barrett J Rollins
Journal:  Blood       Date:  2010-06-02       Impact factor: 22.113

5.  Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.

Authors:  Julien Haroche; Fleur Cohen-Aubart; Jean-François Emile; Laurent Arnaud; Philippe Maksud; Frédéric Charlotte; Philippe Cluzel; Aurélie Drier; Baptiste Hervier; Neïla Benameur; Sophie Besnard; Jean Donadieu; Zahir Amoura
Journal:  Blood       Date:  2012-12-20       Impact factor: 22.113

6.  Therapy prolongation improves outcome in multisystem Langerhans cell histiocytosis.

Authors:  Helmut Gadner; Milen Minkov; Nicole Grois; Ulrike Pötschger; Elfriede Thiem; Maurizio Aricò; Itziar Astigarraga; Jorge Braier; Jean Donadieu; Jan-Inge Henter; Gritta Janka-Schaub; Kenneth L McClain; Sheila Weitzman; Kevin Windebank; Stephan Ladisch
Journal:  Blood       Date:  2013-04-15       Impact factor: 22.113

7.  Somatic activating ARAF mutations in Langerhans cell histiocytosis.

Authors:  David S Nelson; Willemijn Quispel; Gayane Badalian-Very; Astrid G S van Halteren; Cor van den Bos; Judith V M G Bovée; Sara Y Tian; Paul Van Hummelen; Matthew Ducar; Laura E MacConaill; R Maarten Egeler; Barrett J Rollins
Journal:  Blood       Date:  2014-03-20       Impact factor: 22.113

Review 8.  Blood spotlight on Langerhans cell histiocytosis.

Authors:  Christine Delprat; Maurizio Aricò
Journal:  Blood       Date:  2014-06-03       Impact factor: 22.113

9.  BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups.

Authors:  Marie-Luise Berres; Karen Phaik Har Lim; Tricia Peters; Jeremy Price; Hitoshi Takizawa; Hélène Salmon; Juliana Idoyaga; Albert Ruzo; Philip J Lupo; M John Hicks; Albert Shih; Stephen J Simko; Harshal Abhyankar; Rikhia Chakraborty; Marylene Leboeuf; Monique Beltrão; Sérgio A Lira; Kenneth M Heym; Venetia Bigley; Matthew Collin; Markus G Manz; Kenneth McClain; Miriam Merad; Carl E Allen
Journal:  J Exp Med       Date:  2014-03-17       Impact factor: 14.307

10.  High prevalence of MAP2K1 mutations in variant and IGHV4-34-expressing hairy-cell leukemias.

Authors:  Joshua J Waterfall; Evgeny Arons; Robert L Walker; Marbin Pineda; Laura Roth; J Keith Killian; Ogan D Abaan; Sean R Davis; Robert J Kreitman; Paul S Meltzer
Journal:  Nat Genet       Date:  2013-11-17       Impact factor: 38.330
  10 in total
  1 in total

1.  Clinical study of MAP2K1-mutated Langerhans cell histiocytosis in children.

Authors:  Ying Yang; Chanjuan Wang; Dong Wang; Lei Cui; Na Li; Hongyun Lian; Honghao Ma; Yunze Zhao; Liping Zhang; Wei Liu; Yizhuo Wang; Wanshui Wu; Rui Zhang; Zhigang Li; Tianyou Wang
Journal:  J Cancer Res Clin Oncol       Date:  2021-09-30       Impact factor: 4.322
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.